PubMed Health⌕ Search

Biomedical subjects

C Kobayashi

Publications and source records attributed to C Kobayashi.

At least 109 records · Page 6Linked to original sources
PubMed1982

Spontaneous reversal of portal blood flow demonstrated by percutaneous transhepatic catheterization: report of two cases.

Two patients are described in whom percutaneous transhepatic catheterization of the portal vein for a hemodynamic study demonstrated a continuous reversed blood flow in the portal vein, entering into a large collateral. The measurements made of blood pressure in the superior mesenteric, splenic, and left gastric veins, and of ammonia, immunoreactive insulin, and C-peptide in blood taken from these and peripheral veins all indicated reversed portal vein blood flow. The evidence for retrograde portal vein blood flow was obtained in only 2 of 203 patients with cirrhosis in whom portal hemodynamics were studied by the same procedure. Thus, spontaneous reversal of portal vein blood flow does occur, but very rarely.

Blood Pressure↗
PubMed1982

[Studies on defensive factors of experimental ulcers (2). Increasing action of aceglutamide aluminum on defensive factors in acetic acid ulcers of rats (author's transl)].

Severe ulcers were produced in rats by injections of 20% acetic acid in a volume of 0.05 ml into the subserosal layer of two portions in the corpus, and the effects of aceglutamide aluminum on hexosamine, sialic acid, uronic acid and hydroxyproline contents of the mucosa and stroma in the ulcerated regions were compared with the effects of L-glutamine. When aceglutamide aluminum (1,000 mg/kg x 2/day) was orally administered for 4 consecutive days beginning the day of the operation, this drug inhibited the ulcer index and the perforations in ulcerated regions by 18 and 66%, respectively. In addition, the drug remarkably increased the total amounts (microgram/ulcer areas/rat) of hexosamine, sialic acid, and uronic acid in the mucosa of ulcerated regions. It was notable than with the sialic acid contents, an increase in the concentration (microgram/100 mg dry tissue) was also observed. On the other hand, in the stroma of ulcerated regions, the contents of those components containing hydroxyproline were little affected by this drug. Following daily oral administration for 14 consecutive days, aceglutamide aluminum (1,000 mg/kg x 2/day) brought about more potent effects than those following the 4 days administrations, and this drug showed a 37% inhibition of the ulcer index and a complete inhibition of the perforations. Moreover, the drug pronouncedly increased both total amounts and concentrations of hexosamine, sialic acid, and uronic acid in the mucosa in the ulcerated portions. Of these components, the increment of the sialic acid content was the greatest. In the stroma of ulcerated portions, total amounts and concentrations of those components containing hydroxyproline were significantly increased by this drug, although the increase in the stroma were less than those in the mucosa. These effects of aceglutamide aluminum were far more potent than those of L-glutamine at the same dose. From the above results, aceglutamide aluminum may accelerate ulcer repair by potentiating defensive factors through the increases of components forming the mucus and granuloma in ulcerated tissues.

Acetates↗
PubMed1976

[Clinical studies on gentamicin (author's transl)].

UNLABELLED: Gentamicin (GM) was studied for on its antibacterial activity, absorption, and excretion, effect on the kidney and clinical effects. The results obtained are as follows: 1. Antibacterial activity: The susceptibility of E. coli, Klebsiella, Proteus mirabilis to GM was almost the same between the periods of 1964 to 1966 and 1972 to 1974: No tendency of increase of resistance by year was noted. However, against Pseudomonas aeruginosa, strains showing sensitivity to a concentration of more than 25 mcg/ml were isolated in 12.7%, in the latter period (1972-1974), as compared with the former period (1964-1966), which was 0%. 2. Blood levels: The peak level of GM in blood was obtained at 30 minutes after intramuscular injection to a healthy human. The peak level was 7.6 mcg/ml with 40 mg dose, 8.7 mcg/ml with 60 mg and 10.6 mcg/ml with 80 mg, showing a dose-responding curve. The half-life of GM absorption was 1.1 hours with 40 mg dose, 1.3 hours with 60 mg and 1.6 hours with 80 mg, showing also a dose related tendency. 3. Urinary levels: The peak level of GM in urine, about 200 mcg/ml, was noted in 0-2 hours after intramuscular injection of GM to a healthy human. The urinary recovery was about 44% in 6 hours. 4. Effect on the kidney: The effects of GM on the kidney was studied in rats administering 20 mg/kg once a day for 21 days consecutively. The results obtained are a slight increase (20 mg/dl) in BUN and a slight decrease (2,600 mosm/kg H2O) in urinary osmotic pressure; and urea lysozyme showed tendency to increase from the third day, the same as with kanamycin. Meanwhile, in the histopathological findings of the kidney tissue, the vacuolar degeneration and flattening of renal tubules were noted. Similar findings were obtained with kanamycin in a similar type of experiment. These results indicate that nephrotoxicity of GM is considered to be approximately the same as that of kanamycin. 5. CLINICAL RESULTS: GM was injected into 22 patients with various infectious diseases (respiratory tract infections 7, liver abscess 1, urinary tract infections 14). Excellent efficacy was noted in 7 patients, good in 13 and no effect in 2. The effective rate was 90.9%. No serious side effect was noted in this clinical trial.

Adult↗